Pancreatic cancer's notorious resistance to treatment may finally have a molecular explanation that points toward actionable therapeutic targets. The most aggressive basal-like subtype of pancreatic ductal adenocarcinoma hijacks cellular energy factories in an unexpected way, potentially explaining why standard chemotherapy fails so consistently in these patients.
The investigation reveals that keratin 17 (K17), a structural protein typically found in cell frameworks, relocates to mitochondria where it fundamentally alters cancer cell metabolism. Through a specific mitochondrial targeting sequence, K17 enters the intermembrane space and binds to dihydroorotate dehydrogenase (DHODH), stabilizing this enzyme by blocking its normal degradation. This protection allows cancer cells to dramatically increase pyrimidine production—the building blocks needed for DNA synthesis and rapid tumor growth. When researchers blocked K17's mitochondrial entry, pancreatic cancer cells became vulnerable to gemcitabine, the standard chemotherapy drug.
This discovery exposes a previously unknown metabolic dependency that could transform treatment approaches for the deadliest form of pancreatic cancer. The finding that K17-positive tumors rely heavily on enhanced pyrimidine synthesis suggests combination therapy targeting both DHODH and traditional chemotherapy pathways. Animal studies demonstrated that dual DHODH inhibition with gemcitabine doubled survival times specifically in K17-positive tumors, indicating this biomarker could guide personalized treatment decisions. While pancreatic cancer remains among the most challenging malignancies, this mechanistic insight into how basal-like tumors evade therapy represents a significant step toward precision oncology approaches. The work illustrates how fundamental cellular machinery can be co-opted by cancer cells, creating both vulnerability and therapeutic opportunity.